David A. Ricks
Also at Eli Lilly and Co
About
David A. Ricks serves as the Chair, President, and Chief Executive Officer of Eli Lilly and Company, bringing a wealth of experience from a 28-year career at the firm. At 57 years old as of 2024 , his leadership reflects decades of service and strategic guidance across various divisions of the company.
Throughout his distinguished career, he has held key roles including positions in marketing, sales, and international operations, progressing from significant leadership roles such as President of Lilly USA and Senior Vice President & President of Lilly Bio-Medicines to ultimately leading the company as CEO in 2017.
In addition to his executive roles at LLY, he contributes to the broader industry by serving on the board of directors for Adobe Inc. and participating in several industry organizations such as the Pharmaceutical Research and Manufacturers of America and the International Federation of Pharmaceutical Manufacturers & Associations.
$LLY Performance Under David A. Ricks
Past Roles
External Roles
Fixed Compensation
Performance Compensation
Non-Equity Incentive Plan Compensation (Bonus Plan)
2023-2025 Performance Awards (EPS-Based)
2023-2025 Shareholder Value Awards (SVA)
2023-2025 Relative Value Awards (RVA)
Interviews

Eli Lilly CEO David Ricks on Q1 results, weight loss drug competition and status of weight-loss pill

Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025

The David Rubenstein Show: Eli Lilly CEO Dave Ricks

David A Ricks, Chair and Chief Executive Officer of Eli Lilly and Company

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine

Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

Eli Lilly CEO on $27 billion investment in U.S. manufacturing expansion

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic

Seeing More Acceptance Of Mounjaro Across Markets: Eli Lilly's Global CEO David Ricks | CNBC TV19

A Breakthrough in Health: How GLP-1s Are Redefining Pharma with David Ricks and Fatima Cody Stanford

Eli Lilly CEO David Ricks on GLP-1 and obesity drugs

Eli Lilly CEO David Ricks on $.5.3 billion weight loss drug investment

Eli Lilly CEO David Ricks on Q2 results: Seeing unbelievable demand for Zepbound and Mounjaro

Vast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David Ricks
